These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 27404026)
1. Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects. Pinkerton JV; Bushmakin AG; Abraham L; Cappelleri JC; Komm BS Menopause; 2016 Oct; 23(10):1092-101. PubMed ID: 27404026 [TBL] [Abstract][Full Text] [Related]
2. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Bachmann G; Bobula J; Mirkin S Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455 [TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382 [TBL] [Abstract][Full Text] [Related]
4. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning. Pinkerton JV; Bushmakin AG; Komm BS; Abraham L Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177 [TBL] [Abstract][Full Text] [Related]
5. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362 [TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Pinkerton JV; Pickar JH; Racketa J; Mirkin S Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. Bushmakin AG; Abraham L; Pinkerton JV; Cappelleri JC; Mirkin S Menopause; 2014 Aug; 21(8):815-22. PubMed ID: 24378765 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058 [TBL] [Abstract][Full Text] [Related]
9. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Pinkerton JV; Pan K; Abraham L; Racketa J; Ryan KA; Chines AA; Mirkin S Menopause; 2014 Mar; 21(3):252-9. PubMed ID: 23942245 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling. Pinkerton JV; Bushmakin AG; Racketa J; Cappelleri JC; Chines AA; Mirkin S Menopause; 2014 Mar; 21(3):243-51. PubMed ID: 23899830 [TBL] [Abstract][Full Text] [Related]
11. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118 [TBL] [Abstract][Full Text] [Related]
13. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population. Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720 [TBL] [Abstract][Full Text] [Related]
15. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826 [TBL] [Abstract][Full Text] [Related]
16. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial. Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570 [TBL] [Abstract][Full Text] [Related]
17. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women. Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739 [TBL] [Abstract][Full Text] [Related]
18. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo. Kagan R; Abreu P; Andrews E Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946 [TBL] [Abstract][Full Text] [Related]
19. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis. Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562 [TBL] [Abstract][Full Text] [Related]
20. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Mirkin S; Komm BS; Pan K; Chines AA Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]